Journal of Oral and Maxillofacial Surgery
Volume 68, Issue 5 , Pages 1043-1054 , May 2010

Inhibition of Necrotic Actions of Nitrogen-Containing Bisphosphonates (NBPs) and Their Elimination From Bone by Etidronate (a Non-NBP): A Proposal for Possible Utilization of Etidronate as a Substitution Drug for NBPs

  • Takefumi Oizumi, DDS

      Affiliations

    • Student, Department of Maxillofacial Surgery, Graduate School of Dentistry, Tohoku University, Sendai, Japan
    • ,
  • Hiromi Funayama, DDS, PhD

      Affiliations

    • Assistant Professor, Department of Pediatric Dentistry, Tsurumi University, School of Dental Medicine, Yokohama, Japan
    • ,
  • Kouji Yamaguchi, DDS, PhD

      Affiliations

    • Assistant Professor, Department of Maxillofacial Surgery, Graduate School of Dentistry, Tohoku University, Sendai, Japan
    • ,
  • Masayoshi Yokoyama, DDS, PhD

      Affiliations

    • Assistant Professor, Department of Advanced Prosthetic Dentistry, Graduate School of Dentistry, Tohoku University, Sendai, Japan
    • ,
  • Harue Takahashi, DDS

      Affiliations

    • Student, Department of Advanced Prosthetic Dentistry, Graduate School of Dentistry, Tohoku University, Sendai, Japan
    • ,
  • Miou Yamamoto, DDS

      Affiliations

    • Student, Department of Advanced Prosthetic Dentistry, Graduate School of Dentistry, Tohoku University, Sendai, Japan
    • ,
  • Toshinobu Kuroishi, PhD

      Affiliations

    • Assistant Professor, Department of Molecular Regulation, Graduate School of Dentistry, Tohoku University, Sendai, Japan
    • ,
  • Hiroyuki Kumamoto, DDS, PhD

      Affiliations

    • Department of Oral Pathology, Graduate School of Dentistry, Tohoku University, Sendai, Japan
    • ,
  • Keiichi Sasaki, DDS, PhD

      Affiliations

    • Professor, Department of Stomatognathic Physiology and Prosthodontics, Graduate School of Dentistry, Tohoku University, Sendai, Japan
    • ,
  • Hiroshi Kawamura, DDS, PhD

      Affiliations

    • Professor, Department of Maxillofacial Surgery, Graduate School of Dentistry, Tohoku University, Sendai, Japan
    • ,
  • Shunji Sugawara, DDS, PhD

      Affiliations

    • Professor, Department of Molecular Regulation, Graduate School of Dentistry, Tohoku University, Sendai, Japan
    • ,
  • Yasuo Endo, PhD

      Affiliations

    • Associate Professor, Department of Molecular Regulation, Graduate School of Dentistry, Tohoku University, Sendai, Japan
    • Corresponding Author InformationAddress correspondence and reprint request to Dr Endo: Department of Molecular Regulation, Graduate School of Dentistry, 4-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Japan

References 

  1. Geddes AD, D'Souza SM, Ebentino FH, et al. Bisphosphonates: Structure-activity relationships and therapeutic implications. In:  Heershe NM,  Kanis JK editor. Bone and Mineral Research/8. Amsterdam: Elsevier Science BV; 1994;p. 265
  2. Rogers MJ, Gordon S, Benford HL, et al. Cellular and molecular mechanisms of action of bisphosphonates. Cancer. 2000;88:2961
  3. Caraglia M, Santini D, Marra M, et al. Emerging anti-cancer molecular mechanisms of aminobisphosphonates. Endocr Relat Cancer. 2006;13:7
  4. Adami S, Bhalla AK, Dorizzi R, et al. The acute phase response after bisphosphonate administration. Calcif Tissue Int. 1987;41:326
  5. Siris E. Bisphosphonates and iritis. Lancet. 1993;341:436
  6. Macarol V, Frauenfelder FT. Pamidronate disodium and possible ocular adverse drug reactions. Am J Ophthamol. 1994;118:220
  7. Sauty A, Pecherstorfer M, Zimmer-Roth I, et al. Interleukin-6 and tumor necrosis factor α levels after bisphosphonates treatment in vitro and in patients with malignancy. Bone. 1996;18:133
  8. Fleisch HA. Bisphosphonates: Preclinical aspects and use in osteoporosis. Ann Med. 1997;29:56
  9. Thiébaud D, Sauty A, Burckhardt P, et al. An in vitro and in vivo study of cytokines in the acute-phase response associated with bisphosphonates. Calcif Tissue Int. 1997;61:386
  10. Munns CF, Rauch F, Mier RJ, et al. Respiratory distress with pamidronate treatment in infants with severe osteogenesis imperfecta. Bone. 2004;35:231
  11. Ruggiero S, Mebrotra B, Rosenberg TJ, et al. Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases. J Oral Maxillofac Surg. 2004;62:527
  12. Marx RE, Sawatari Y, Fortin M, et al. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: Risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg. 2005;63:1767
  13. Woo SB, Hellstein JW, Kalmar JR. Systematic review: Bisphosphonates and osteonecrosis of the jaws. Ann Intern Med. 2006;144:753
  14. Pazianas M, Miller P, Blimentals WA, et al. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: Prevalence, risk factors, and clinical characteristics. Clin Ther. 2007;29:1548
  15. Shimahara M, Ariyoshi Y, Imai Y, et al. A survey of bisphosphonate-related osteomyelitis/osteonecrosis of the jaw. Jpn J Oral Surg. 2007;53:16;(Japanese, abstract in English)
  16. Novartis. Home page. October 13, 2009;http://www.novartis.co.jp/product/zom/te/te_arezom0607.html
  17. Hellstein JW, Marek CL. Bisphosphonate osteochemonecrosis (bis-phossy jaw): Is this phossy jaw of the 21st century?. J Oral Maxillofac Surg. 2005;63:682
  18. Migliorati CA, Siegel MA, Elting LS. Bisphosphonate-associated osteonecrosis: A long-term complication of bisphosphonate treatment. Lancet Oncol. 2006;7:508
  19. Endo Y, Nakamura N, Kikuchi T, et al. Aminoalkylbisphosphonates, potent inhibitors of bone resorption, induce a prolonged stimulation of histamine synthesis and increase macrophages, granulocytes, and osteoclasts in vivo. Calcif Tissue Int. 1993;52:248
  20. Endo Y, Shibazaki M, Nakamura M, et al. Inhibition of inflammatory actions of aminobisphosphonates by dichloromethylene bisphosphonate, a non-aminobisphosphonate. Br J Pharmacol. 1999;126:903
  21. Nakamura M, Yagi H, Endo Y, et al. A time kinetic study of the effect of aminobisphosphonate on murine haemopoiesis. Br J Haematol. 1999;107:779
  22. Sugawara S, Shibazaki M, Takada H, et al. Contrasting effects of an aminobisphosphonate, a potent inhibitor of bone resorption, on lipopolysaccharide-induced production of interleukin-1 and tumour necrosis factor α in mice. Br J Pharmacol. 1998;125:735
  23. Funayama H, Mayanagi H, Takada H, et al. Elevation of histidine decarboxylase activity in the mandible of mice by Prevotella intermedia lipopolysaccharide and its augmentation by an aminobisphosphonate. Arch Oral Biol. 2000;45:787
  24. Yamaguchi K, Motegi K, Iwakura Y, et al. Involvement of interleukin-1 in the inflammatory actions of aminobisphosphonates in mice. Br J Pharmacol. 2000;130:1646
  25. Deng X, Yu Z, Funayama H, et al. Mutual augmentation of the induction of the histamine-forming enzyme, histidine decarboxylase, between alendronate and immuno-stimulants (IL-1, TNF, and LPS), and its prevention by clodronate. Toxicol Appl Pharmacol. 2006;213:64
  26. Funayama H, Ohsako M, Monma Y, et al. Inhibition of inflammatory and bone-resorption-inhibitory effects of alendronate by etidronate. Calcif Tissue Int. 2005;76:448
  27. Lewington VJ. Cancer therapy using bone-seeking isotopes. Phys Med Biol. 1996;41:2027
  28. Horai R, Asano M, Sudo K, et al. Production of mice deficient in genes for interleukin(IL)-1α, IL-1β, IL-1α/β, and IL-1 receptor antagonist shows that IL-1β is crucial in turpentine-induced fever development and glucocorticoid secretion. J Exp Med. 1998;187:1463
  29. Yu Z, Funayama H, Deng X, et al. Comparative appraisal of clodronate, aspirin and dexamethasone as agents reducing alendronate-induced inflammation in a murine model. Basic Clin Pharmacol Toxicol. 2005;97:222
  30. Monma Y, Funayama H, Mayanagi H, et al. Effects of weekly administrations of alendronate + clodronate on young mouse tibia: Localized action at the proximal growth plate. Calcif Tissue Int. 2004;74:115
  31. Sasaki H, Koyama S, Yokoyama M, et al. Bone metabolic activity around dental implants under loading observed using bone scintigraphy. Int J Oral Maxillofac Implants. 2008;23:827
  32. Mönkkönen J, Koponen H-M, Ylitalo P. Comparison of the distribution of three bisphosphonates in mice. Pharmacol Toxicol. 1989;65:294
  33. Deng X, Yu Z, Funayama H, et al. Histidine decarboxylase-stimulating and inflammatory effects of alendronate in mice: Involvement of mevalonate pathway, TNFα, macrophages, and T-cells. Int Immunopharmacol. 2007;7:152
  34. Roelofs AJ, Thompson K, Gordon S, et al. Molecular mechanisms of action of bisphosphonates: Current status. Clin Cancer Res. 2006;12(suppl):6222s
  35. Sato M, Grasser W, Endo N, et al. Bisphosphonate action: Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest. 1991;88:2095
  36. Newton CJ, Ran G, Xie YX, et al. Statin-induced apoptosis of vascular endothelial cells is blocked by dexamethasone. J Endocrinol. 2002;174:7
  37. Gniadecki R. Depletion of membrane cholesterol causes ligand-independent activation of Fas and apoptosis. Biochem Biophys Res Commun. 2004;320:165
  38. Gober H-J, Kistowska M, Angman L, et al. Human T-cell receptor γδ cells recognize endogenous mevalonate metabolites in tumor cells. J Exp Med. 2003;197:163
  39. Thompson K, Rogers MJ. Statins prevent bisphosphonate-induced γ, δ-T-cell proliferation and activation in vitro. J Bone Miner Res. 2004;19:278
  40. Kunzmann V, Bauer E, Feurle J, et al. Stimulation of γδ T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood. 2000;96:384
  41. Miyagawa F, Tanaka Y, Yamashita S, et al. Essential requirement of antigen presentation by monocyte lineage cells for the activation of primary human γδ T cells by aminobisphosphonate antigen. J Immunol. 2001;166:5508
  42. Mariani S, Muraro M, Panteleoni F, et al. Effector γδ T cells and tumor cells as immune targets of zoledronic acid in multiple myeloma. Leukemia. 2005;19:664
  43. Bürk MR, Carena I, Donda A, et al. Functional inactivation in the whole population of human Vγ9/Vδ2 T lymphocytes induced by a nonpeptidic antagonist. J Exp Med. 1997;185:91
  44. Mestas J, Hughes CCW. Of mice and not men: Differences between mouse and human immunology. J Immunol. 2004;172:2731
  45. Girardi M. Immunosurveillance and immunoregulation by γδ T cells. J Investig Dermatol. 2006;126:25
  46. Mandey SHL, Kuijk LM, Frenkel J, et al. A role for geranylgeranylation in interleukin-1 secretion. Arthritis Rheum. 2006;54:3690
  47. Lin JH, Chen IW, Duggan DE. Effects of dose, sex, and age on the disposition of alendronate, a potent antiosteolytic bisphosphonate, in rats. Drug Metab Dispos. 1992;20:473
  48. Yamaguchi K, Oizumi T, Funayama H, et al. Osteonecrosis of jawbone in 2 osteoporosis patients treated with nitrogen-containing bisphosphonate: Osteonecrosis reduction replacing NBP with non-NBP (etidronate) and rationale. J Oral Maxillofac Surg. 2010;(in press)

PII: S0278-2391(09)01633-4

doi: 10.1016/j.joms.2009.08.027

Journal of Oral and Maxillofacial Surgery
Volume 68, Issue 5 , Pages 1043-1054 , May 2010

Article Tools

* Image Usage & Resolution